-
Mashup Score: 0Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds - MedCity News - 3 hour(s) ago
Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1This Chip Seeks to Transform Drug Manufacturing by Learning More About Intracellular Dynamics - MedCity News - 19 hour(s) ago
A new startup launched at the SynBioBeta conference. The company, called CybergenX, is seeking to integrate AI-powered cybergenetic technology into the synthetic biology field. By doing this, CybergenX is seeking to accelerate the potential of engineering biology in drug manufacturing.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0ŌURA Unveils 2 New Features for Heart Health - MedCity News - 20 hour(s) ago
ŌURA announced two new heart health features on Friday: one that estimates cardiovascular age and one that measures cardio capacity.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Small Thank You’s Mean a Lot: The Impact of Micropayments in Clinical Trials - MedCity News - 22 hour(s) ago
Micropayments provide an additional incentive for patients to complete required tests, procedures, and diary entries, ensuring that sites, sponsors, and CROs are able to collect the required data needed to complete a clinical trial on time and on budget.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1INVEST 2024 - 1 day(s) ago
Join us to hear from innovative investors and entrepreneurs offering novel approaches to solve some of healthcare’s greatest challenges.
Source: www.eventbrite.comCategories: General Medicine News, General NewsTweet-
The INVEST 2024 Agenda is full of insights for healthcare professionals. Plus, we’re the industry's premier networking, uniting active investors with corporate business development executives to facilitate investment opportunities. Save $700 now. https://t.co/tujwz4IPNy #mcINVEST https://t.co/s6ZzpyF95l
-
-
Mashup Score: 3
Check out news from Alpha Sophia, Triomics, In-House Health, and Humanaut Health.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4Astellas CEO Q&A (Part 1): There Is No Playbook on Cell and Gene Therapies - MedCity News - 1 day(s) ago
A Q&A with Naoki Okamura revealed that when it comes to cell and gene therapies, the CEO of Astellas Pharma believes risk-taking is a must for eventual success.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Ascension Hospitals Across Several States Are Offline Following Cyberattack - MedCity News - 2 day(s) ago
On Wednesday, Ascension noticed that a hacker had infiltrated its systems. As the health system works with Mandiant to investigate the incident, clinical services remain disrupted at Ascension facilities across several states.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Why Consumers Leave Their Payer/Provider - MedCity News - 2 day(s) ago
Many consumers leave their provider because of navigation problems, while many leave their insurer because of experience issues, a new Accenture report found.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer - MedCity News - 2 day(s) ago
Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies.
Source: medcitynews.comCategories: General Medicine News, General NewsTweet
Monthly dosing of experimental Amgen #obesity med MariTide translates to fewer days sick from GLP-1 side effects vs. weekly injectables Wegovy and Zepbound. For @Amgen, less frequent dosing eases the burden of manufacturing enough drug to meet demand. https://t.co/sWvNPAejz3